Knowledge (XXG)

Intetumumab

Source 📝

1444: 1387: 1531: 74: 234: 1492: 1428: 402: 34: 811: 1511: 1485: 1421: 1343: 1012: 1232: 395: 1526: 1521: 869: 796: 701: 1478: 1414: 726: 388: 711: 816: 675: 346: 131: 1360: 454: 919: 1516: 1348: 1315: 1256: 1207: 1122: 746: 1286: 1276: 1246: 1037: 982: 909: 899: 776: 1261: 1250: 1212: 1102: 1087: 1017: 997: 992: 771: 525: 1112: 972: 741: 706: 1458: 1394: 1227: 1197: 1192: 1177: 1007: 854: 806: 766: 411: 255: 95: 44: 27: 465: 949: 500: 460: 339: 321: 836: 655: 313: 1462: 1398: 305: 176: 104: 140: 1455: 277: 1451: 1354: 1320: 987: 309: 1505: 1202: 1057: 610: 445: 325: 1217: 1182: 1167: 1162: 1157: 1152: 1127: 1082: 1077: 1072: 1067: 1052: 939: 914: 894: 756: 721: 660: 640: 450: 435: 380: 296:Łasiñska I, Mackiewicz J (2019). "Integrins as A New Target for Cancer Treatment". 360: 1325: 1299: 1294: 1266: 1242: 1237: 1172: 1147: 1137: 1107: 1097: 1062: 1047: 1032: 1022: 1002: 977: 962: 934: 884: 879: 874: 859: 849: 826: 821: 791: 736: 680: 670: 645: 635: 630: 625: 600: 575: 565: 560: 555: 545: 515: 510: 495: 490: 480: 475: 470: 440: 1443: 1386: 1271: 1222: 1187: 1117: 1092: 1042: 1027: 967: 957: 929: 904: 844: 786: 781: 716: 696: 650: 620: 615: 605: 595: 590: 580: 570: 540: 535: 505: 485: 215: 115: 340:"Statement On A Nonproprietary Name Adopted By The USAN Council: Intetumumab" 1142: 1132: 924: 889: 864: 801: 761: 751: 731: 665: 585: 550: 520: 20: 317: 420: 273: 266: 259: 61: 56: 160: 49: 280:
were in progress when development of the drug was discontinued.
151: 384: 262:
that was being studied for the treatment of solid tumors.
1466: 1402: 241: 1308: 1285: 948: 835: 689: 428: 419: 214: 175: 170: 150: 130: 114: 94: 89: 73: 68: 55: 43: 33: 26: 103: 1532:Antineoplastic and immunomodulating drug stubs 1486: 1422: 396: 8: 19: 1493: 1479: 1429: 1415: 425: 403: 389: 381: 272:Phase II clinical trials for treatment of 298:Anti-Cancer Agents in Medicinal Chemistry 139: 288: 18: 7: 1440: 1438: 1383: 1381: 159: 1465:. You can help Knowledge (XXG) by 1401:. You can help Knowledge (XXG) by 14: 310:10.2174/1871520618666181119103413 1442: 1385: 193: 187: 1512:Drugs not assigned an ATC code 205: 199: 181: 1: 265:Intetumumab was developed by 347:American Medical Association 1548: 1437: 1380: 171:Chemical and physical data 1527:Monoclonal antibody stubs 1522:Experimental cancer drugs 1338: 920:Mirvetuximab soravtansine 231: 1316:Depatuxizumab mafodotin 1257:Tucotuzumab celmoleukin 1208:Rovalpituzumab tesirine 1123:Lorvotuzumab mertansine 1013:Clivatuzumab tetraxetan 1397:–related article is a 1277:Vorsetuzumab mafodotin 1233:Tacatuzumab tetraxetan 1038:Denintuzumab mafodotin 983:Bivatuzumab mertansine 910:Loncastuximab tesirine 900:Indatuximab ravtansine 777:Naptumomab estafenatox 1262:Vandortuzumab vedotin 1213:Sacituzumab govitecan 1103:Inotuzumab ozogamicin 1088:Gemtuzumab ozogamicin 1018:Cofetuzumab pelidotin 998:Cantuzumab ravtansine 993:Cantuzumab mertansine 812:Nofetumomab merpentan 772:Moxetumomab pasudotox 526:Glembatumumab vedotin 412:Monoclonal antibodies 1309:Chimeric + humanized 1113:Lifastuzumab vedotin 973:Belantamab mafodotin 742:Ibritumomab tiuxetan 707:Anatumomab mafenatox 1395:monoclonal antibody 1228:Sofituzumab vedotin 1198:Polatuzumab vedotin 1193:Pinatuzumab vedotin 1178:Oportuzumab monatox 1008:Citatuzumab bogatox 870:Derlotuximab biotin 855:Brentuximab vedotin 807:Taplitumomab paptox 797:Satumomab pendetide 767:Nacolomab tafenatox 702:Altumomab pentetate 256:monoclonal antibody 28:Monoclonal antibody 23: 16:Monoclonal antibody 1365:Never to phase III 727:Capromab pendetide 501:Enfortumab vedotin 1474: 1473: 1410: 1409: 1375: 1374: 1334: 1333: 656:Tisotumab vedotin 249: 248: 1539: 1495: 1488: 1481: 1456:immunomodulatory 1446: 1439: 1431: 1424: 1417: 1389: 1382: 1287:Rat/mouse hybrid 426: 405: 398: 391: 382: 376: 375: 373: 371: 357: 351: 350: 344: 336: 330: 329: 293: 245: 244: 237: 226: 224: 207: 201: 195: 189: 183: 163: 143: 107: 24: 22: 1547: 1546: 1542: 1541: 1540: 1538: 1537: 1536: 1517:Janssen Biotech 1502: 1501: 1500: 1499: 1436: 1435: 1378: 1376: 1371: 1370: 1355:Clinical trials 1330: 1304: 1281: 944: 831: 685: 415: 409: 379: 369: 367: 359: 358: 354: 342: 338: 337: 333: 295: 294: 290: 286: 278:prostate cancer 240: 238: 235:(what is this?) 232: 222: 220: 210: 204: 198: 192: 186: 166: 146: 126: 110: 85: 17: 12: 11: 5: 1545: 1543: 1535: 1534: 1529: 1524: 1519: 1514: 1504: 1503: 1498: 1497: 1490: 1483: 1475: 1472: 1471: 1452:antineoplastic 1447: 1434: 1433: 1426: 1419: 1411: 1408: 1407: 1390: 1373: 1372: 1369: 1368: 1367: 1366: 1363: 1352: 1346: 1340: 1339: 1336: 1335: 1332: 1331: 1329: 1328: 1323: 1321:Duvortuxizumab 1318: 1312: 1310: 1306: 1305: 1303: 1302: 1297: 1291: 1289: 1283: 1282: 1280: 1279: 1274: 1269: 1264: 1259: 1254: 1240: 1235: 1230: 1225: 1220: 1215: 1210: 1205: 1200: 1195: 1190: 1185: 1180: 1175: 1170: 1165: 1160: 1155: 1150: 1145: 1140: 1135: 1130: 1125: 1120: 1115: 1110: 1105: 1100: 1095: 1090: 1085: 1080: 1075: 1070: 1065: 1060: 1055: 1050: 1045: 1040: 1035: 1030: 1025: 1020: 1015: 1010: 1005: 1000: 995: 990: 988:Brontictuzumab 985: 980: 975: 970: 965: 960: 954: 952: 946: 945: 943: 942: 937: 932: 927: 922: 917: 912: 907: 902: 897: 892: 887: 882: 877: 872: 867: 862: 857: 852: 847: 841: 839: 833: 832: 830: 829: 824: 819: 814: 809: 804: 799: 794: 789: 784: 779: 774: 769: 764: 759: 754: 749: 744: 739: 734: 729: 724: 719: 714: 709: 704: 699: 693: 691: 687: 686: 684: 683: 678: 673: 668: 663: 658: 653: 648: 643: 638: 633: 628: 623: 618: 613: 608: 603: 598: 593: 588: 583: 578: 573: 568: 563: 558: 553: 548: 543: 538: 533: 528: 523: 518: 513: 508: 503: 498: 493: 488: 483: 478: 473: 468: 463: 458: 455:+hyaluronidase 448: 443: 438: 432: 430: 423: 417: 416: 410: 408: 407: 400: 393: 385: 378: 377: 352: 331: 304:(5): 580–586. 287: 285: 282: 247: 246: 229: 228: 218: 212: 211: 208: 202: 196: 190: 184: 179: 173: 172: 168: 167: 165: 164: 156: 154: 148: 147: 145: 144: 136: 134: 128: 127: 125: 124: 120: 118: 112: 111: 109: 108: 100: 98: 92: 91: 87: 86: 84: 83: 79: 77: 71: 70: 66: 65: 59: 53: 52: 47: 41: 40: 39:Whole antibody 37: 31: 30: 15: 13: 10: 9: 6: 4: 3: 2: 1544: 1533: 1530: 1528: 1525: 1523: 1520: 1518: 1515: 1513: 1510: 1509: 1507: 1496: 1491: 1489: 1484: 1482: 1477: 1476: 1470: 1468: 1464: 1461:article is a 1460: 1457: 1453: 1448: 1445: 1441: 1432: 1427: 1425: 1420: 1418: 1413: 1412: 1406: 1404: 1400: 1396: 1391: 1388: 1384: 1379: 1364: 1362: 1359: 1358: 1356: 1353: 1350: 1347: 1345: 1342: 1341: 1337: 1327: 1324: 1322: 1319: 1317: 1314: 1313: 1311: 1307: 1301: 1298: 1296: 1293: 1292: 1290: 1288: 1284: 1278: 1275: 1273: 1270: 1268: 1265: 1263: 1260: 1258: 1255: 1252: 1248: 1244: 1241: 1239: 1236: 1234: 1231: 1229: 1226: 1224: 1221: 1219: 1216: 1214: 1211: 1209: 1206: 1204: 1203:Rosmantuzumab 1201: 1199: 1196: 1194: 1191: 1189: 1186: 1184: 1181: 1179: 1176: 1174: 1171: 1169: 1166: 1164: 1161: 1159: 1156: 1154: 1151: 1149: 1146: 1144: 1141: 1139: 1136: 1134: 1131: 1129: 1126: 1124: 1121: 1119: 1116: 1114: 1111: 1109: 1106: 1104: 1101: 1099: 1096: 1094: 1091: 1089: 1086: 1084: 1081: 1079: 1076: 1074: 1071: 1069: 1066: 1064: 1061: 1059: 1058:Enoblituzumab 1056: 1054: 1051: 1049: 1046: 1044: 1041: 1039: 1036: 1034: 1031: 1029: 1026: 1024: 1021: 1019: 1016: 1014: 1011: 1009: 1006: 1004: 1001: 999: 996: 994: 991: 989: 986: 984: 981: 979: 976: 974: 971: 969: 966: 964: 961: 959: 956: 955: 953: 951: 947: 941: 938: 936: 933: 931: 928: 926: 923: 921: 918: 916: 913: 911: 908: 906: 903: 901: 898: 896: 893: 891: 888: 886: 883: 881: 878: 876: 873: 871: 868: 866: 863: 861: 858: 856: 853: 851: 848: 846: 843: 842: 840: 838: 834: 828: 825: 823: 820: 818: 815: 813: 810: 808: 805: 803: 800: 798: 795: 793: 790: 788: 785: 783: 780: 778: 775: 773: 770: 768: 765: 763: 760: 758: 755: 753: 750: 748: 745: 743: 740: 738: 735: 733: 730: 728: 725: 723: 720: 718: 715: 713: 710: 708: 705: 703: 700: 698: 695: 694: 692: 688: 682: 679: 677: 674: 672: 669: 667: 664: 662: 659: 657: 654: 652: 649: 647: 644: 642: 639: 637: 634: 632: 629: 627: 624: 622: 619: 617: 614: 612: 611:Pembrolizumab 609: 607: 604: 602: 599: 597: 594: 592: 589: 587: 584: 582: 579: 577: 574: 572: 569: 567: 564: 562: 559: 557: 554: 552: 549: 547: 544: 542: 539: 537: 534: 532: 529: 527: 524: 522: 519: 517: 514: 512: 509: 507: 504: 502: 499: 497: 494: 492: 489: 487: 484: 482: 479: 477: 474: 472: 469: 467: 464: 462: 459: 456: 452: 449: 447: 446:Ascrinvacumab 444: 442: 439: 437: 434: 433: 431: 427: 424: 422: 418: 413: 406: 401: 399: 394: 392: 387: 386: 383: 366: 362: 361:"Intetumumab" 356: 353: 348: 341: 335: 332: 327: 323: 319: 315: 311: 307: 303: 299: 292: 289: 283: 281: 279: 275: 270: 268: 263: 261: 257: 253: 243: 236: 230: 219: 217: 213: 180: 178: 174: 169: 162: 158: 157: 155: 153: 149: 142: 138: 137: 135: 133: 129: 122: 121: 119: 117: 113: 106: 102: 101: 99: 97: 93: 88: 81: 80: 78: 76: 72: 69:Clinical data 67: 63: 60: 58: 54: 51: 48: 46: 42: 38: 36: 32: 29: 25: 1467:expanding it 1449: 1403:expanding it 1392: 1377: 1218:Sibrotuzumab 1183:Parsatuzumab 1168:Otlertuzumab 1163:Odronextamab 1158:Ocaratuzumab 1153:Obinutuzumab 1128:Lumretuzumab 1083:Flotetuzumab 1078:Ficlatuzumab 1073:Farletuzumab 1068:Etaracizumab 1053:Emibetuzumab 940:Zolbetuximab 915:Margetuximab 895:Girentuximab 757:Minretumomab 722:Blinatumomab 661:Teprotumumab 641:Seribantumab 530: 466:Botensilimab 451:Atezolizumab 436:Adecatumumab 368:. Retrieved 364: 355: 334: 301: 297: 291: 271: 264: 251: 250: 239:   233:   1351:from market 1326:Ontuxizumab 1300:Ertumaxomab 1295:Catumaxomab 1267:Vanucizumab 1247:+deruxtecan 1243:Trastuzumab 1238:Tigatuzumab 1173:Onartuzumab 1148:Nimotuzumab 1138:Milatuzumab 1108:Labetuzumab 1098:Imgatuzumab 1063:Epcoritamab 1048:Emactuzumab 1033:Dalotuzumab 1023:Dacetuzumab 1003:Cirmtuzumab 978:Bevacizumab 963:Alemtuzumab 935:Ublituximab 885:Ensituximab 880:Ecromeximab 875:Dinutuximab 860:Carotuximab 850:Bavituximab 827:Tositumomab 822:Tenatumomab 792:Racotumomab 737:Edrecolomab 712:Arcitumomab 681:Zalutumumab 671:Vantictumab 646:Sugemalimab 636:Robatumumab 631:Rilotumumab 626:Ramucirumab 601:Panitumumab 576:Necitumumab 566:Mapatumumab 561:Lucatumumab 556:Lexatumumab 546:Istiratumab 531:Intetumumab 516:Flanvotumab 511:Figitumumab 496:Dusigitumab 491:Duligotumab 481:Daratumumab 476:Conatumumab 471:Cixutumumab 461:Balstilimab 441:Amivantamab 365:AdisInsight 254:is a human 252:Intetumumab 227: g·mol 105:725735-28-4 90:Identifiers 21:Intetumumab 1506:Categories 1272:Veltuzumab 1251:+emtansine 1223:Simtuzumab 1188:Pertuzumab 1118:Lintuzumab 1093:Glofitamab 1043:Elotuzumab 1028:Demcizumab 968:Axatilimab 958:Abituzumab 930:Siltuximab 905:Isatuximab 845:Amatuximab 817:Pintumomab 787:Pemtumomab 782:Oregovomab 717:Bectumomab 697:Abagovomab 651:Tarextumab 621:Radretumab 616:Pritumumab 606:Patritumab 596:Olaratumab 591:Ofatumumab 581:Nesvacumab 571:Narnatumab 541:Iratumumab 536:Ipilimumab 506:Enoticumab 486:Drozitumab 414:for tumors 370:30 January 284:References 258:targeting 216:Molar mass 141:GQE1BJE2NI 116:ChemSpider 96:CAS Number 1361:Phase III 1349:Withdrawn 1143:Naxitamab 1133:Matuzumab 950:Humanized 925:Rituximab 890:Futuximab 865:Cetuximab 802:Solitomab 762:Mitumomab 752:Lilotomab 732:Detumomab 676:Votumumab 666:Tovetumab 586:Nivolumab 551:Icrucumab 521:Ganitumab 260:integrins 837:Chimeric 747:Igovomab 326:53952455 318:30451118 274:melanoma 267:Centocor 242:(verify) 75:ATC code 62:integrin 269:, Inc. 177:Formula 64:alpha-V 1344:WHO-EM 324:  316:  161:D09631 57:Target 45:Source 1450:This 1393:This 690:Mouse 429:Human 421:Tumor 343:(PDF) 322:S2CID 191:10008 50:Human 1463:stub 1459:drug 1399:stub 372:2017 314:PMID 276:and 203:2006 197:1744 185:6468 152:KEGG 132:UNII 123:none 82:none 35:Type 1454:or 306:doi 225:.81 223:579 221:145 1508:: 1357:: 1249:/ 363:. 345:. 320:. 312:. 302:19 300:. 209:40 1494:e 1487:t 1480:v 1469:. 1430:e 1423:t 1416:v 1405:. 1253:) 1245:( 457:) 453:( 404:e 397:t 390:v 374:. 349:. 328:. 308:: 206:S 200:O 194:N 188:H 182:C

Index

Monoclonal antibody
Type
Source
Human
Target
integrin
ATC code
CAS Number
725735-28-4
ChemSpider
UNII
GQE1BJE2NI
KEGG
D09631
Formula
Molar mass
(what is this?)
(verify)
monoclonal antibody
integrins
Centocor
melanoma
prostate cancer
doi
10.2174/1871520618666181119103413
PMID
30451118
S2CID
53952455
"Statement On A Nonproprietary Name Adopted By The USAN Council: Intetumumab"

Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.